Company Overview - Clearmind Medicine Inc. is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address under-treated health issues, particularly Alcohol Use Disorder (AUD) [1][7] - The company has a proprietary drug candidate, CMND-100, which is based on MEAI and aims to provide a novel treatment approach for AUD by modulating reward mechanisms associated with addictive behavior [4] Clinical Trial Initiation - Clearmind has initiated its Phase I/IIa clinical trial for CMND-100 at Johns Hopkins University School of Medicine, marking a significant milestone towards FDA approval [1][3] - The trial will also take place at Yale School of Medicine and IMCA Center in Israel, indicating a strong foundation for evaluating the clinical potential of CMND-100 [2][3] Study Objectives - The clinical trial is designed to assess the safety, tolerability, and pharmacokinetics of CMND-100 in individuals diagnosed with AUD, along with preliminary efficacy evaluations to examine its potential in reducing alcohol cravings and consumption [3] Market Context - Alcohol Use Disorder is a major global health challenge, affecting approximately 400 million people aged 15 and older, with 209 million experiencing alcohol dependence [6] - The disorder contributes to 2.6 million deaths annually, accounting for 4.7% of all global deaths, highlighting the urgent need for innovative therapeutic solutions [6] Regulatory and Intellectual Property - Clearmind aims to commercialize its psychedelic-based compounds as regulated medicines, foods, or supplements, and currently holds a portfolio of nineteen patent families with 31 granted patents [7][8]
Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder